Evidence map›Paper›PMID 42578759›Full record

ReviewActa dermato-venereologica2026

Redefining Treat-to-target in Atopic Dermatitis: Towards Meaningful, Patient-centred Disease Control - An ISAD Position Paper.

John Su, Andreas Wollenberg, Melanie Funk, Tina Mesarič, Brandon Hu, Tammi Shipowick, Kelly Barta, Kristin Belleson, Li-Chuen Wong, Kiu Han Kim and 20 more

Abstract readReviewConsensus Statement
In one paragraph

Review in Acta dermato-venereologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

John SuDepartment of Dermatology, Monash University, Eastern Health and Murdoch Children's Research Institute, Royal Children's Hospital, Melbourne, Australia; International Society of Atopic Dermatitis (ISAD), Davos, Switzerland.
Andreas WollenbergInternational Society of Atopic Dermatitis (ISAD), Davos, Switzerland; Department of Dermatology and Allergy, University Hospital Augsburg, Augsburg, Germany; Comprehensive Center for Inflammation Medicine, University Hospital Schleswig-Holstein, Lübeck, Germany; Department of Dermatology and Allergy, Ludwig Maximilian University, Munich, Germany.
Melanie FunkEczema Support Australia, Hope Island, Australia.
Tina MesaričInstitute Atopika, Maribor, Slovenia.
Brandon HuDepartment of Dermatology, Monash University, Eastern Health and Murdoch Children's Research Institute, Royal Children's Hospital, Melbourne, Australia; Independent patient representative and physician trainee, Melbourne, Australia.
Tammi ShipowickGlobalSkin, Ottawa, Canada.
Kelly BartaInternational Topical Steroid Awareness Network (ITSAN), Atlanta, GA, United States.
Kristin BellesonNational Eczema Association, Novato, CA, United States.
Li-Chuen WongDepartment of Dermatology, The Children's Hospital at Westmead, Sydney, Australia.
Kiu Han KimDepartment of Dermatology, VHS Medical Center, Seoul, South Korea.
Chia-Yu ChuDepartment of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
Sandipan DharInternational Society of Atopic Dermatitis (ISAD), Davos, Switzerland; Department of Pediatric Dermatology, Kolkata, India.
Yoshiyuki KataokaDepartment of Dermatology, Osaka Habikino Medical Center, Osaka, Japan.
Kin Fon LeongDepartment of Dermatology, Kuala Lumpur, Malaysia.
Kam Lun Ellis HonDepartment of Pediatrics, CUHK Medical Centre, The Chinese University of Hong Kong, Hong Kong, China.
Erere OtrofanoweiInternational Society of Atopic Dermatitis (ISAD), Davos, Switzerland; Dermatology Unit, Department of Medicine, College of Medicine, University of Lagos, Lagos, Nigeria.
Peter FoleyDepartment of Dermatology, Monash University, Eastern Health and Murdoch Children's Research Institute, Royal Children's Hospital, Melbourne, Australia; Skin Health Institute and The University of Melbourne, Melbourne, Australia.
Lin MaInternational Society of Atopic Dermatitis (ISAD), Davos, Switzerland; Department of Dermatology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Yong Kwang TayDepartment of Dermatology, Changi General Hospital, Singapore, Singapore.
Marie LodénDepartment of Dermatology and Pharmacy, Stockholm, Sweden.
Anousha YazdabadiDepartment of Dermatology, Eastern Health Clinical School, Monash Medical School, Monash University, Melbourne, Australia.
Kathrin A GibsonDepartment of Rheumatology, Liverpool Hospital, Sydney, Australia.
Jonathan D AkikusaRheumatology Service, Department of General Medicine, Royal Children's Hospital, Melbourne, Australia.
Andrew ÖstörRheumatology Service, Department of General Medicine, Royal Children's Hospital, Melbourne, Australia.
Connie KatelarisAllergy and Immunology Unit, Department of Medicine, Campbelltown Hospital, Sydney, Australia.
Frank ThienDepartment of Respiratory Medicine, Monash University, Eastern Health, Melbourne, Australia.
Michihiro FutamuraDepartment of Pediatrics and Allergy, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Rie YotsuDepartment of Tropical Medicine and Infectious Disease, Celia Scott Weatherhead School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA, United States.
Peter Schmid-GrendelmeierInternational Society of Atopic Dermatitis (ISAD), Davos, Switzerland; Allergy Unit, Department of Dermatology, University Hospital Zurich, Switzerland, Davos; CK-CARE, Davos, Switzerland.
Alain TaïebInternational Society of Atopic Dermatitis (ISAD), Davos, Switzerland. alain.taieb@u-bordeaux.fr.ORCID 0000-0002-0928-8608

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Treat-to-target strategies link predefined goals to regular assessment and treatment adaptation. In atopic dermatitis, recent initiatives have mainly defined thresholds using clinician- and patient-reported outcomes. This review and position paper critically examines current approaches and proposes priorities for a more clinically meaningful, patient-centred and globally applicable framework. It synthesizes recent consensus and outcome-harmonization initiatives with selected lessons from rheumatoid arthritis and asthma and was informed by multidisciplinary, patient-inclusive discussions at an International Society of Atopic Dermatitis-World Health Organization premeeting. The workshop was not a Delphi or formal consensus exercise; it was used to identify conceptual priorities and implementation challenges for future international consensus work. Current proposals converge partly around severity thresholds and symptom control but insufficiently capture disease instability, comorbidities, family burden, treatment burden and real-world constraints. We propose 4 complementary domains: disease activity; symptoms and function; global patient health and disease impact and longitudinal control and treatment adaptation. Some components are supported by validated measures, whereas others remain exploratory. Treat-to-target in atopic dermatitis should evolve beyond isolated thresholds towards an adaptable multidimensional strategy, followed by formal international consensus and prospective validation.

Indexed as

Dermatitis, AtopicPatient-Centered CareCost of IllnessHumansPatient Reported Outcome MeasuresSeverity of Illness IndexTreatment Outcome

Identifiers

PMID42578759
PMCPMC13459419

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.